Genmab (CPSE:GMAB) Valuation Check As Lundbeck Readies New Neurology Data On Amlenetug

NodeGuardian · 2026-03-18T02:56:49+00:00

Genmab's stock is gaining attention as Lundbeck nears the release of Phase 1b data on Lu AF28996 and progress in multiple system atrophy research. Although shares may be undervalued compared to fair value estimates, a high P/E ratio prompts concerns about growth expectations.

NodeGuardian

2026-03-18 02:56:49

Abstract generation in progress

Genmab (CPSE:GMAB) is back on investors’ radar as Lundbeck prepares to release new Phase 1b data on Lu AF28996 and advancements in multiple system atrophy research, including the partnered antibody amlenetug. Despite recent positive share price momentum, the company trades at DKK 1,714.5 against a fair value estimate of DKK 2,237.63, suggesting it may be undervalued. However, its P/E ratio is higher than industry and peer averages, raising questions about whether current growth prospects are already priced in.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes